Opioid class REMS will not delay new drug approvals, FDA says
This article was originally published in Scrip
Executive Summary
Ongoing deliberations over a single risk evaluation and mitigation strategy (REMS) for long-acting and sustained-release opioids will not block approval of new drugs within the class, US FDA office of new drugs director Dr John Jenkins said.